Prognostic relevance of response evaluation using [18F]-2- fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8362-8370

  Hoekstra, Corneline J ^a   Stroobants, Sigrid C ^a   Smit, Egbert F ^a   Vansteenkiste, Johan ^a   Van Tinteren, Harm ^a   Postmus, Pieter E ^a   Golding, Richard P ^a   Biesma, Bonne ^a   Schramel, Frans J H M ^a   Van Zandwijk, Nico ^a   Lammertsma, Adriaan A ^a   Hoekstra, Otto S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; VINDESINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; METABOLIC RATE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG MONITORING; EUROPE; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCINTISCANNING; SINGLE BLIND PROCEDURE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG MONITORING; EUROPE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS;

EID: 33644663786     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.1189     Document Type: Article

References (36)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 32:205-216, 2000
2. Rusch V, Giroux D, Kraut M, et al: Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): Mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). Proc Am Soc Clin Oncol 22:634, 2003 (abstr 2548)
3. Werner-Wasik M, Xiao Y, Pequignot E, et al: Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume-A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56-61, 2001
4. Andre F, Grunenwald D, Pignon JP, et al: Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol 18:2981-2989, 2000
5. Eberhardt WE, Albain KS, Pass H, et al: induction treatment before surgery for non-small cell lung cancer. Lung Cancer 42:39-14, 2003 (suppl 1)
6. Weber WA, Petersen V, Schmidt B, et al: Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651-2657, 2003
7. Kalff V, Hicks RJ, MacManus MP, et al: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol 19:111-118, 2001
8. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small cell lung cancer: An analysis of 125 cases-Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999
9. Ryu JS, Choi NC, Fischman AJ, et al: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology. Lung Cancer 35:179-187, 2002
10. Cerfolio RJ, Ojha B, Mukherjee S, et al: Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 125:938-944, 2003
11. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell iung cancer: A prospective pilot study-The Leuven Lung Cancer Group. Ann Oncol 9:1193-1198, 1998
12. Mac Manus MP, Hicks RJ, Matthews JP, et al: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285-1292, 2003
13. Patz EF, Connolly J, Herndon J: Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174:769-774, 2000
14. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al: Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods. Eur J Nucl Med 27:731-743, 2000
15. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
16. Lorent N, Vansteenkiste J, De Leyn PR, et al: Long-term survival of surgically staged IIIA-N2 non-small cell lung cancer treated with surgical combined modality approach: Analysis of a 7-year experience. Ann Oncol 15:1645-1653, 2004
17. Hoekstra CJ, Stroobants SG, Hoekstra OS, et al: The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 39:151-157, 2003
18. Boellaard R, van Balen SC, Lammertsma AA: Optimization of attenuation correction for PET studies of thorax and pelvis using countased transmission scans. J Nucl Med 42:196, 2001
19. Hoekstra CJ, Hoekstra OS, Lammertsma AA: On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies. Eur J Nucl Med 26:1489-1492, 1999
20. van der Weerdt AP, Klein LJ, Boellaard R, et al: Image-derived input functions for determination of MRGIu in cardiac (18)F-FDG PET scans. J Nucl Med 42:1622-1629, 2001
21. Boellaard R, Krak NC, Hoekstra OS, et al: Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med 45:1519-1527, 2004
22. Boellaard R, van Lingen A, Lammertsma AA: Experimental and clinical evaluation of iterative reconstruction (osem) in dynamic PET: Quantitative characteristics and effects on kinetic modeling. J Nucl Med 42:808-817, 2001
23. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al: Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304-1309, 2002
24. Hunter GJ, Hamberg LM, Alpert NM, et al: Simplified measurement of deoxyglucose utilization rate. J Nucl Med 37:950-955, 1996
25. Akaike H: A new look at the statistical identification. IEEE Trans Automat Contr 19:716-723, 1978
26. Port JL, Kent MS, Korst RJ, et al: Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 77:254-259, 2004
27. Taylor NA, Liao ZX, Cox JD, et al: Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204-212, 2004
28. Downey RJ, Akhurst T, Ilson D, et al: Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 21:428-432, 2003
29. Downey RJ, Akhurst T, Gonen M, et al: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255-3260, 2004
30. Weber WA, Ziegler SI, Thodtmann R, et al: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777, 1999
31. Stahl A, Ott K, Schwaiger M, Weber WA: Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31:1471-1478, 2004
32. Krak NC, Boellaard R, Hoekstra OS, et al: Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 32:294-301, 2005
33. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al: Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: Analysis of the literature. Lung Cancer 19:3-13, 1998
34. Keyes JW Jr: SUV: Standard uptake or silly useless value? J Nucl Med 36:1836-1839, 1995
35. Krak NC, van der Hoeven JJM, Hoekstra OS, etal: Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods. Eur J Nucl Med Mol Imaging 30:674-681, 2003
36. Kroep JR, van Groeningen CJ, Cuesta MA, et al: Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: A comparison of different analytical methods. Mol Imaging Biol 5:337-346, 2003